Clinical observation of Cinacalcet in the treatment of secondary hyperparathyroidism in hemodialysis patients

Objective To discuss the clinical effects of Cinacalcet--a calcium sensitive receptor agonist in maintenance hemodialysis(MDH)patients with secondary hyperparathyroidism(SHPT).Methods Ninety-eight MDH patients with SHPT admitted at the Fifth Hospital of Wuhan were divided into the observation group(...

Full description

Saved in:
Bibliographic Details
Main Authors: ZHANG Xin, ZHOU Huan, WANG Xiao-hui, HE Yong, PENG Qing-ping
Format: Article
Language:zho
Published: Editorial Department of Journal of Clinical Nephrology 2018-01-01
Series:Linchuang shenzangbing zazhi
Subjects:
Online Access:http://www.lcszb.com/thesisDetails?columnId=57915895&Fpath=home&index=0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850274427791474688
author ZHANG Xin
ZHOU Huan
WANG Xiao-hui
HE Yong
PENG Qing-ping
author_facet ZHANG Xin
ZHOU Huan
WANG Xiao-hui
HE Yong
PENG Qing-ping
author_sort ZHANG Xin
collection DOAJ
description Objective To discuss the clinical effects of Cinacalcet--a calcium sensitive receptor agonist in maintenance hemodialysis(MDH)patients with secondary hyperparathyroidism(SHPT).Methods Ninety-eight MDH patients with SHPT admitted at the Fifth Hospital of Wuhan were divided into the observation group(n=49)and the control group(n=49).The patients in the control group were treated with conventional treatments such as phosphate binding agent,vitamin D analogue,and those in the observation group were given Cinacalcet besides the treatments in the control group.The clinical effects were compared between the two groups.The changes in blood urea nitrogen,creatinine and KT/V were compared between the two groups.Results The effective rate in the observation group was 87.8%,significantly higher than 67.3% in the control group(P<0.05).Blood calcium phosphorus,ALP,and iPTH levels in the two groups were significantly reduced after the treatment(P<0.01),and those in the observation group were significantly lower than in the control group(P<0.01).There was no significantly difference in BUN,SCr,and KT/V between the two groups(P>0.05).The size of the parathyroid glands was significantly smaller after treatment than before treatment in both two groups(P<0.01),and that in the observation group was significantly smaller than in the control group(P<0.01).The incidence of adverse reactions in the observation group was 14.3%,significantly lower than 40.8% in the control group(P<0.01).Conclusions Cinacalcet has exactly effective in MDH patients with SHPT.Cinacalcet can effectively reduce the level of parathyroid hormone and the size of the parathyroid glands,with less adverse reactions,and is worthy of promotion.
format Article
id doaj-art-b0d5c266cbce4220ba35efa2585983bf
institution OA Journals
issn 1671-2390
language zho
publishDate 2018-01-01
publisher Editorial Department of Journal of Clinical Nephrology
record_format Article
series Linchuang shenzangbing zazhi
spelling doaj-art-b0d5c266cbce4220ba35efa2585983bf2025-08-20T01:51:09ZzhoEditorial Department of Journal of Clinical NephrologyLinchuang shenzangbing zazhi1671-23902018-01-0115615957915895Clinical observation of Cinacalcet in the treatment of secondary hyperparathyroidism in hemodialysis patientsZHANG XinZHOU HuanWANG Xiao-huiHE YongPENG Qing-pingObjective To discuss the clinical effects of Cinacalcet--a calcium sensitive receptor agonist in maintenance hemodialysis(MDH)patients with secondary hyperparathyroidism(SHPT).Methods Ninety-eight MDH patients with SHPT admitted at the Fifth Hospital of Wuhan were divided into the observation group(n=49)and the control group(n=49).The patients in the control group were treated with conventional treatments such as phosphate binding agent,vitamin D analogue,and those in the observation group were given Cinacalcet besides the treatments in the control group.The clinical effects were compared between the two groups.The changes in blood urea nitrogen,creatinine and KT/V were compared between the two groups.Results The effective rate in the observation group was 87.8%,significantly higher than 67.3% in the control group(P<0.05).Blood calcium phosphorus,ALP,and iPTH levels in the two groups were significantly reduced after the treatment(P<0.01),and those in the observation group were significantly lower than in the control group(P<0.01).There was no significantly difference in BUN,SCr,and KT/V between the two groups(P>0.05).The size of the parathyroid glands was significantly smaller after treatment than before treatment in both two groups(P<0.01),and that in the observation group was significantly smaller than in the control group(P<0.01).The incidence of adverse reactions in the observation group was 14.3%,significantly lower than 40.8% in the control group(P<0.01).Conclusions Cinacalcet has exactly effective in MDH patients with SHPT.Cinacalcet can effectively reduce the level of parathyroid hormone and the size of the parathyroid glands,with less adverse reactions,and is worthy of promotion.http://www.lcszb.com/thesisDetails?columnId=57915895&Fpath=home&index=0CinacalcetHemodialysisSecondary hyperparathyroidism
spellingShingle ZHANG Xin
ZHOU Huan
WANG Xiao-hui
HE Yong
PENG Qing-ping
Clinical observation of Cinacalcet in the treatment of secondary hyperparathyroidism in hemodialysis patients
Linchuang shenzangbing zazhi
Cinacalcet
Hemodialysis
Secondary hyperparathyroidism
title Clinical observation of Cinacalcet in the treatment of secondary hyperparathyroidism in hemodialysis patients
title_full Clinical observation of Cinacalcet in the treatment of secondary hyperparathyroidism in hemodialysis patients
title_fullStr Clinical observation of Cinacalcet in the treatment of secondary hyperparathyroidism in hemodialysis patients
title_full_unstemmed Clinical observation of Cinacalcet in the treatment of secondary hyperparathyroidism in hemodialysis patients
title_short Clinical observation of Cinacalcet in the treatment of secondary hyperparathyroidism in hemodialysis patients
title_sort clinical observation of cinacalcet in the treatment of secondary hyperparathyroidism in hemodialysis patients
topic Cinacalcet
Hemodialysis
Secondary hyperparathyroidism
url http://www.lcszb.com/thesisDetails?columnId=57915895&Fpath=home&index=0
work_keys_str_mv AT zhangxin clinicalobservationofcinacalcetinthetreatmentofsecondaryhyperparathyroidisminhemodialysispatients
AT zhouhuan clinicalobservationofcinacalcetinthetreatmentofsecondaryhyperparathyroidisminhemodialysispatients
AT wangxiaohui clinicalobservationofcinacalcetinthetreatmentofsecondaryhyperparathyroidisminhemodialysispatients
AT heyong clinicalobservationofcinacalcetinthetreatmentofsecondaryhyperparathyroidisminhemodialysispatients
AT pengqingping clinicalobservationofcinacalcetinthetreatmentofsecondaryhyperparathyroidisminhemodialysispatients